Literature DB >> 25671272

A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm.

Xénia Cabagnols1, Jean-Michel Cayuela, William Vainchenker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25671272     DOI： 10.1056/NEJMc1413718

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

2.  Buccal epithelial cells display somatic, bone marrow-derived CALR mutation.

Authors:  Scott R Gilles; Linda B Baughn; Matthew L Schomaker; Elizabeth L Courville; Andrew C Nelson; Zohar Sachs
Journal:  Blood Adv       Date:  2017-11-16

Review 3.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.

Authors:  Xavier Cahu; Stefan N Constantinescu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 4.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Authors:  Elisa Rumi; Mario Cazzola
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

5.  CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.

Authors:  Irene Dogliotti; Carmen Fava; Anna Serra; Enrico Gottardi; Filomena Daraio; Francesca Carnuccio; Emilia Giugliano; Monica Bocchia; Giuseppe Saglio; Giovanna Rege-Cambrin
Journal:  Stem Cell Investig       Date:  2017-06-23

6.  Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies.

Authors:  Joseph Saliba; Cécile Saint-Martin; Antonio Di Stefano; Gaëlle Lenglet; Caroline Marty; Boris Keren; Florence Pasquier; Véronique Della Valle; Lise Secardin; Gwendoline Leroy; Emna Mahfoudhi; Sarah Grosjean; Nathalie Droin; M'boyba Diop; Philippe Dessen; Sabine Charrier; Alberta Palazzo; Jane Merlevede; Jean-Côme Meniane; Christine Delaunay-Darivon; Pascal Fuseau; Françoise Isnard; Nicole Casadevall; Eric Solary; Najet Debili; Olivier A Bernard; Hana Raslova; Albert Najman; William Vainchenker; Christine Bellanné-Chantelot; Isabelle Plo
Journal:  Nat Genet       Date:  2015-08-17       Impact factor: 38.330

7.  Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.

Authors:  Lasse Kjær; Sabrina Cordua; Morten O Holmström; Mads Thomassen; Torben A Kruse; Niels Pallisgaard; Thomas S Larsen; Karin de Stricker; Vibe Skov; Hans C Hasselbalch
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

8.  Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia.

Authors:  Anaïse Blouet; Marie-Christine Rousselet; Yannick Le Bris; Bénédicte Ribourtout; Anne Bouvier; Laurane Cottin; Rébecca Jouanneau-Courville; Odile Blanchet; Valérie Ugo; Damien Luque Paz
Journal:  Hemasphere       Date:  2018-02-05

9.  Diagnostic and therapeutic implications of genetic heterogeneity in myeloid neoplasms uncovered by comprehensive mutational analysis.

Authors:  Sarah M Choi; Ben Goldenson; Lo Ann Peterson; Shira Dinner; Brady L Stein; Amir Behdad
Journal:  Leuk Res Rep       Date:  2017-09-20

Review 10.  Philadelphia+ Chronic Myeloid Leukemia with CALR Mutation: A Case Report and Literature Review.

Authors:  Seug Yun Yoon; Sun Young Jeong; Changgon Kim; Min-Young Lee; Jieun Kim; Kyoung-Ha Kim; Namsu Lee; Jong-Ho Won
Journal:  Cancer Res Treat       Date:  2020-01-15       Impact factor: 4.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.